1. Home
  2. PSN vs KYMR Comparison

PSN vs KYMR Comparison

Compare PSN & KYMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Parsons Corporation

PSN

Parsons Corporation

N/A

Current Price

$56.90

Market Cap

7.7B

Sector

Technology

ML Signal

N/A

Logo Kymera Therapeutics Inc.

KYMR

Kymera Therapeutics Inc.

N/A

Current Price

$77.47

Market Cap

6.8B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PSN
KYMR
Founded
1944
2015
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Medicinal Chemicals and Botanical Products
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.7B
6.8B
IPO Year
2019
2020

Fundamental Metrics

Financial Performance
Metric
PSN
KYMR
Price
$56.90
$77.47
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
13
26
Target Price
$83.50
$108.04
AVG Volume (30 Days)
1.3M
697.7K
Earning Date
05-13-2026
05-18-2026
Dividend Yield
N/A
N/A
EPS Growth
3.77
N/A
EPS
2.20
N/A
Revenue
$6,364,245,000.00
$39,211,000.00
Revenue This Year
$6.08
$16.05
Revenue Next Year
$7.63
$4.79
P/E Ratio
$26.73
N/A
Revenue Growth
N/A
N/A
52 Week Low
$56.27
$19.45
52 Week High
$89.50
$103.00

Technical Indicators

Market Signals
Indicator
PSN
KYMR
Relative Strength Index (RSI) 30.05 39.91
Support Level N/A $77.78
Resistance Level $68.13 $95.90
Average True Range (ATR) 1.77 4.56
MACD -0.75 -1.45
Stochastic Oscillator 0.56 7.09

Price Performance

Historical Comparison
PSN
KYMR

About PSN Parsons Corporation

Parsons Corp is a provider of technology-driven solutions in the defense, intelligence, and critical infrastructure markets. The business activities of the group are carried out through Federal Solutions and Critical Infrastructure segments. The Federal Solutions segment is a high-end service and technology provider to the U.S. government, delivering timely, cost-effective solutions for mission-critical projects, whereas the Critical Infrastructure segment provides integrated design and engineering services for complex physical and digital infrastructure around the globe.

About KYMR Kymera Therapeutics Inc.

Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.

Share on Social Networks: